Trial · NCT03029247
Outcomes57
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 57
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57 | Up to 6 hours post dose on Day 57 | Intent-to-Treat (ITT)-Population comprised of all randomized participants who received at least one dose of study treatment. Only those participants with data available at the specified time points were analyzed. | Millimeters of mercury (mmHg) | LEAST_SQUARES_MEAN |
| SECONDARY | Average of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1 | Up to 6 hours post dose on Day 1 | ITT Population. Only those participants with data available at the specified time points were analyzed. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1 | Up to 6 hours post dose on Day 1 | ITT Population. Only those participants with data available at the specified time points were analyzed. | Beats per minute | LEAST_SQUARES_MEAN |
| SECONDARY | Area Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1 | Up to 24 hours post dose on Day 1 | ITT Population. Only those participants with data available at the specified time points were analyzed. | mmHg*Hours | LEAST_SQUARES_MEAN |
| SECONDARY | AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1 | Up to 24 hours post dose on Day 1 | ITT Population. Only those participants with data available at the specified time points were analyzed. | Beats per minute*Hours | LEAST_SQUARES_MEAN |
| SECONDARY | Average of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57 | Up to 6 hours post dose on Day 57 | ITT Population. Only those participants with data available at the specified time points were analyzed. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57 | Up to 6 hours post dose on Day 57 | ITT Population. Only those participants with data available at the specified time points were analyzed. | Beats per minute | LEAST_SQUARES_MEAN |
| SECONDARY | AUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57 | Up to 24 hours post dose on Day 57 | ITT Population. Only those participants with data available at the specified time points were analyzed. | mmHg*Hours | LEAST_SQUARES_MEAN |
| SECONDARY | AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57 | Up to 24 hours post dose on Day 57 | ITT Population. Only those participants with data available at the specified time points were analyzed. | Beats per minute*Hours | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Pre-dose in SBP, DBP and MAP at Day 1 | Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose | ITT-Population. Only those participants with data available at specified time points has been presented (represented as n=X in category titles). | mmHg | MEAN |
| SECONDARY | Change From Pre-dose in HR at Day 1 | Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose | ITT-Population. Only those participants with data available at specified time points has been presented (represented as n=X in category titles). | Beats per minute | MEAN |
| SECONDARY | Plasma Concentrations of Daprodustat | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population comprised of all participants in the Safety population who had at least 1 non-missing pharmacokinetic assessment. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Plasma Concentrations of Metabolite GSK2391220 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Plasma Concentrations of Metabolite GSK2506104 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Plasma Concentrations of Metabolite GSK2487818 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Plasma Concentrations of Metabolite GSK2506102 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Plasma Concentrations of Metabolite GSK2531398 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Plasma Concentrations of Metabolite GSK2531401 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | MEAN |
| SECONDARY | Maximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Nanograms per milliliter | GEOMETRIC_MEAN |
| SECONDARY | Time of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401 | Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57 | Pharmacokinetic Population. Only those participants with data available at specified time points has been presented (represented as n=X in the category titles). | Hours | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03029247/outcomes